Safety of mass drug coadministration with ivermectin, diethylcarbamazine, albendazole, and azithromycin for the integrated treatment of neglected tropical diseases: a cluster randomized community trial

John, Lucy N.; González-Beiras, Camila; Vall-Mayans, Martí; Kolmau, Reman; Houinei, Wendy; Wangi, James; Marks, Michael; Mitjà, Oriol

doi:10.1016/j.lanwpc.2021.100293

Cited by 9 publications

(9 citation statements)

References 12 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A strength of the current study over this previous work is the use of consistent definitions and approaches to adverse event monitoring throughout the whole trial. 19 Collectively, these data suggest that co-administration is an acceptable and safe approach to tackling co-endemic NTDs.…”

Section: Discussionmentioning

confidence: 97%

Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia

McPherson¹,

Tafese²,

Tafese³

et al. 2023

eClinicalMedicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia

McPherson¹,

Tafese²,

Tafese³

et al. 2023

eClinicalMedicine

View full text Add to dashboard Cite

“…In areas with co-endemic filariasis and yaws, IDA can be safely combined with azithromycin, the mass treatment for Yaws. 22 Work is being completed to determine whether the single-dose triple therapy is safe for patients with co-existing filariasis and onchocerciasis. A recent pilot study demonstrated promising results, showing that IDA could be well tolerated after pretreatment with ivermectin to clear the microfilariae in the skin and eyes.…”

Section: New Treatment Optionsmentioning

confidence: 99%

“…IDA is also a practical regimen that can be safely integrated with mass treatment of other conditions. In areas with co‐endemic filariasis and yaws, IDA can be safely combined with azithromycin, the mass treatment for Yaws 22 …”

Section: New Treatment Optionsmentioning

confidence: 99%

Tropical infectious diseases and the skin: Diagnostic and treatment updates since the WHO's integrated campaign against neglected tropical skin diseases

Kim,

Burningham,

Tyring

2023

Dermatological Reviews

View full text Add to dashboard Cite

IntroductionThe World Health Organization (WHO) initiated a unified effort to address skin‐related neglected tropical diseases (NTDs) in 2017. This effort increased attention and resources allocated toward decreasing the burden of tropical skin diseases. It emphasized an “integrated approach” to detect and treat multiple co‐existing NTDs at once. This article will outline new diagnostic tests, treatment options, and vaccine development for neglected tropical skin diseases since the initiative began.Data SourcesA PubMed search of clinical trials, randomized controlled trials, systematic reviews, and meta‐analyses published since 2017 was performed.ResultsThe WHO's initiative has already seen success, increasing the surveillance of leprosy and the distribution of treatment for yaws. It has encouraged the development of new point‐of‐care tests and better‐tolerated treatment options. It has also brought new challenges, with the rise of resistant organisms. Development of point‐of‐care DNA‐RNA‐based testing may improve drug resistance monitoring. New vaccines are needed for long‐term control of skin NTDs in areas with high transmission rates.

show abstract

“…For other patterns of NTD co-endemicity, additional drug combinations have been tested for safety and efficacy and used in pilot programs, but are not yet recommended by the WHO [35][36][37][38][39][40][41][42][43][44][45][46][47]. For example, the WHO does not recommend coadministration of azithromycin with other NTD drugs or coadministration of praziquantel with ivermectin or DEC.…”

Section: Who Data On Neglected Tropical Disease Endemicity and Recomm...mentioning

confidence: 99%

Safety of integrated preventive chemotherapy for neglected tropical diseases

et al. 2022

View full text Add to dashboard Cite

Background Preventive chemotherapy (PC) is a central strategy for control and elimination of neglected tropical diseases (NTDs). Increased emphasis has been given to “integration” of NTD programs within health systems and coadministration of NTD drugs offers significant programmatic benefits. Guidance from the World Health Organization (WHO) reflects current evidence for safe drug coadministration and highlights measures to prevent choking of young children during PC. Methodology To understand how coadministration of NTD drugs might affect PC safety, we reviewed literature on choking risk in young children and safety of coadministered NTD drugs. To understand current practices of drug coadministration, we surveyed 15 NTD program managers and implementing partners. Principal findings In high-income countries, choking on medication is an infrequent cause of death in young children. In low-resource settings, data are limited, but age-appropriate drug formulations are less available. During PC, fatal choking, although infrequent, occurs primarily in young children; forcing them to swallow tablets appears to be the major risk factor. The WHO currently recommends 6 drugs and 5 possible drug combinations for use in PC. Of 105 nations endemic for the 5 PC-NTDs, 72 (68.6%) are co-endemic for 2 or more diseases and could benefit from drug coadministration during PC. All 15 survey respondents reported coadministering medications during PC. Reported responses to a child refusing to take medicine included: not forcing the child to do so (60.0%), encouraging the child (46.7%), bringing the child back later (26.7%), offering powder for oral suspension (POS) for azithromycin (13.3%), and having parents or community members intervene to calm the child (6.7%). Conclusions Coadministration of NTD drugs during PC appears to be increasingly common. Safety of coadministered PC drugs requires attention to choking prevention, use of approved drug combinations, and increased access to age-appropriate drug formulations.

show abstract

Safety of mass drug coadministration with ivermectin, diethylcarbamazine, albendazole, and azithromycin for the integrated treatment of neglected tropical diseases: a cluster randomized community trial

Cited by 9 publications

References 12 publications

Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia

Safety of integrated mass drug administration of azithromycin, albendazole and ivermectin versus standard treatment regimens: a cluster-randomised trial in Ethiopia

Tropical infectious diseases and the skin: Diagnostic and treatment updates since the WHO's integrated campaign against neglected tropical skin diseases

Safety of integrated preventive chemotherapy for neglected tropical diseases

Contact Info

Product

Resources

About